Targeting Tau Pathology Offers New Path for Alzheimer's Drug Development

Research identifies HDAC7 as a druggable target to disrupt tau hyperphosphorylation in Alzheimer's disease models

A study published November 12, 2026, identifies HDAC7 as a potential target for disrupting tau pathology in Alzheimer's disease. Researchers found that HDAC7 stabilizes GSK3β in neurons, promotes tau hyperphosphorylation, and binds to hyperphosphorylated tau via its N-terminal domain. Depleting HDAC7 in mouse models (aged 2 and 13 months) improved cognitive function in Morris water maze and novel object recognition tests, while reducing tau phosphorylation and increasing synaptic protein levels. Human brain tissue from Alzheimer's patients shows evidence of HDAC7-GSK3β-tau complex formation, supporting the target's relevance across species.

This work provides a mechanistic pathway for interventions targeting tau aggregation—a core feature of Alzheimer's disease. The study explicitly identifies HDAC7 as a druggable target via tau pathology, though the findings remain confined to preclinical models. Human tauopathies involve multiple tau isoforms beyond those tested in mice, creating significant complexity for translation.

This represents a potential pathway for future interventions but does not yet move cognitive health toward accessibility. Next steps include validating HDAC7's role in human tauopathies and developing targeted therapies that account for isoform diversity. The current research remains in early stages, with no human trials underway. For now, the pathway exists but requires substantial validation before clinical impact.

Source: Lifespan.io